Results 31 to 40 of about 75,785 (301)

IgM and IgD B cell receptors differentially respond to endogenous antigens and control B cell fate. [PDF]

, 2018
Naive B cells co-express two BCR isotypes, IgM and IgD, with identical antigen-binding domains but distinct constant regions. IgM but not IgD is downregulated on autoreactive B cells. Because these isotypes are presumed to be redundant, it is unknown how
Brombacher, Frank, Garrett-Sinha, Lee Ann, Mueller, James L, Noviski, Mark, Satterthwaite, Anne, Zikherman, Julie   +5 more
core   +3 more sources

Unifying heterogeneous expression data to predict targets for CAR-T cell therapy

OncoImmunology, 2021
Chimeric antigen receptor (CAR) T-cell therapy combines antigen-specific properties of monoclonal antibodies with the lytic capacity of T cells. An effective and safe CAR-T cell therapy strategy relies on identifying an antigen that has high expression ...
Patrick Schreiner, Mireya Paulina Velasquez, Stephen Gottschalk, Jinghui Zhang, Yiping Fan   +4 more
doaj   +1 more source

CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing [PDF]

, 2019
BACKGROUND: Chimeric antigen receptor (CAR)-based T cell therapy is in early clinical trials to target the neuroectodermal tumor, neuroblastoma. No preclinical or clinical efficacy data are available for retinoblastoma to date.
Andersch, Lena, Eggert, Angelika, Flemmig, Carina, Grunewald, Laura, Henssen, Anton, Jensen, Michael C., Joussen, Antonia, Klaus, Anika, Künkele, Annette, Radke, Josefine, Rossig, Claudia, Schulte, Johannes H., Schumann, Elisa, Schwiebert, Silke, Winkler, Annika, Zirngibl, Felix   +15 more
core   +2 more sources

BAFF activation of the ERK5 MAP kinase pathway regulates B cell survival [PDF]

, 2015
B cell activating factor (BAFF) stimulation of the BAFF receptor (BAFF-R) is essential for the homeostatic survival of mature B cells. Earlier in vitro experiments with inhibitors that block MEK 1 and 2 suggested that activation of ERK 1 and 2 MAP ...
Jacque, E, Ley, SC, Schweighoffer, E, Tybulewicz, VL   +3 more
core   +1 more source

Chimeric antigen receptor–modified T cells: CD19 and the road beyond [PDF]

Blood, 2018
Abstract The ability to harness a patient’s immune system to target malignant cells is now transforming the treatment of many cancers, including hematologic malignancies. The adoptive transfer of T cells selected for tumor reactivity or engineered with natural or synthetic receptors has emerged as an effective modality, even for patients
Alexander I. Salter, Margot J. Pont, Stanley R. Riddell   +2 more
openaire   +2 more sources

Targeting antigen to CD19 on B cells efficiently activates T cells [PDF]

International Immunology, 2005
CD19 is a B cell-surface molecule that participates as an important regulatory signaling complex for antigen bound at the surface by Ig. Triggering of CD19 through its linkage with CD21 amplifies signals transduced through the Src family kinases and modulates B cell differentiation in response to antigen.
Jun, Yan, Martin J, Wolff, Julia, Unternaehrer, Ira, Mellman, Mark J, Mamula   +4 more
openaire   +2 more sources

Distinct and shared B cell responses of tuberculosis patients and their household contacts

PLoS ONE, 2022
This study was aimed at identifying the B cell responses which could distinguish between ‘latent tuberculosis infection (LTBI)’ and active TB disease. Study subjects were smear-positive TB patients (n = 54) and their disease-free household contacts (HHCs,
Komal Singh, Rajesh Kumar, Fareha Umam, Prerna Kapoor, Sudhir Sinha, Amita Aggarwal   +5 more
doaj  

CAR-tropic extracellular vesicles carry tumor-associated antigens and modulate CAR T cell functionality

Scientific Reports, 2023
Tumor-derived extracellular vesicles (EVs) are active contributors in metastasis and immunosuppression in tumor microenvironment. At least some of the EVs carry tumor surface molecules such as tumor-associated antigens (TAAs) and/or checkpoint inhibitors,
V. M. Ukrainskaya, O. E. Musatova, D. V. Volkov, D. S. Osipova, D. S. Pershin, A. M. Moysenovich, E. G. Evtushenko, E. A. Kulakovskaya, E. G. Maksimov, H. Zhang, Y. P. Rubtsov, M. A. Maschan, A. V. Stepanov, A. G. Gabibov   +13 more
doaj   +1 more source

Flow Cytometric Analysis of T, B, and NK Cells Antigens in Patients with Mycosis Fungoides

Journal of Immunology Research, 2015
We retrospectively analyzed the clinicopathological correlation and prognostic value of cell surface antigens expressed by peripheral blood mononuclear cells in patients with mycosis fungoides (MF). 121 consecutive MF patients were included in this study.
Serkan Yazıcı, Emel Bülbül Başkan, Ferah Budak, Barbaros Oral, Şaduman Balaban Adim, Zübeyde Ceylan Kalin, Güven Özkaya, Kenan Aydoğan, Hayriye Saricaoğlu, Şükran Tunali   +9 more
doaj   +1 more source

Characterization of novel CD19-specific VHHs isolated from a camelid immune library by phage display

Journal of Translational Medicine, 2023
Background Monoclonal antibody (mAb)-based immunotherapies have achieved promising outcomes in the treatment of immunological and oncological indications. CD19 is considered one of the most qualified antigens in the treatment of B-cell neoplasms.
Mahmoud Ganji, Pooria Safarzadeh Kozani, Fatemeh Rahbarizadeh   +2 more
doaj   +1 more source